Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 384,327 shares at $13.75 ($5.2M) on 2024-12-04, disclosed to the SEC on 2024-12-04.
Scheduled sale ($5.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.55 | 96,343 | $1.3M | 25.3% |
| 2 | $13.55 | 96,343 | $1.3M | 25.3% |
| 3 | $14.34 | 901 | $13K | 0.3% |
| 4 | $13.26 | 87,984 | $1.2M | 22.6% |
| 5 | $13.26 | 87,984 | $1.2M | 22.6% |
| 6 | $13.75 | 14,772 |
| $203K |
| 3.9% |
| Total | $13.43 avg | 384,327 | $5.2M | 100% |
| Filing → |
| SPRY | SELL | 2025-02-04 | $616K | — | Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2023-09-05 | $771K | — | Filing → |